Pyrimidine ring compound

Patent metadata

Field	Value
Publication number	US-12570653-B2
Application number	US-202118041540-A
Country	US
Kind code	B2
Filing date	Aug 17, 2021
Priority date	Aug 17, 2020
Publication date	Mar 10, 2026
Grant date	Mar 10, 2026

Abstract

A pyrimidine ring compound represented by formula (III), or a pharmaceutically acceptable salt thereof, and an application thereof in preparation of a medication for treating related diseases.

First claim

The invention claimed is:

1 . A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,

wherein, ring A is 3-10 membered heterocycloalkyl, and the 3-10 membered heterocycloalkyl is optionally substituted by 1, 2, or 3 R a ;
W is selected from and

R 5 ;
ring B is selected from C 3-8 cycloalkyl, 5-6 membered heteroaryl and 3-10 membered heterocycloalkyl, and the C 3-8 cycloalkyl, 5-6 membered heteroaryl and 3-10 membered heterocycloalkyl are independently and optionally substituted by 1, 2, or 3 Rb;
X is C(R c );
Y is selected from single bond, —NH— and —O—; -L is —S(═O) 2 —;
R 1 is selected from H, halogen, C 1-3 alkyl, C 1-3 alkoxy and —C(═O)—C 1-3 alkyl, and the C 1-3 alkyl, C 1-3 alkoxy and —C(═O)—C 1-3 alkyl are independently and optionally substituted by 1, 2, or 3 R d ;
R 2 and R 3 are independently selected from H, halogen, OH, CN, NH 2 and C 1-8 alkyl, and the C 1-8 alkyl is optionally substituted by 1, 2, or 3 Re;
R 4 is selected from NH 2 , —NH—C 1-6 alkyl, —NH(CN), —NH(OH), C 1-6 alkyl, —N(CN)—C 1-6 alkyl and —N(OH)—C 1-6 alkyl, and the—NH—C 1-6 alkyl, C 1-6 alkyl, —N(CN)—C 1-6 alkyl and —N(OH)—C 1-6 alkyl are independently and optionally substituted by 1, 2, or 3 Rf;
R 5 is selected from C 1-3 alkyl optionally substituted by 1, 2, or 3 R g ;
R c is selected from H, F, Cl, Br, I and CH 3 ;
R a is independently selected from F, Cl, Br, I, CH 3 , OCH 3 , OH, NH 2 , CN, COOH;
R a , R b , R e and R f are independently selected from F, Cl, Br, I, OH, CN, CH 3 , CH 3 CH 2 , CH 3 CH 2 CH 2 , CH(CH 3 ) 2 , OCH 3 , OCF 3 , CHF 2 , CH 2 F and NH 2 ;
R g is independently selected from F, Cl, Br, I, OH, CN and CH 3 ;
the 3-10 membered heterocycloalkyl, 5-6 membered heteroaryl and 3-10 membered heterocycloalkenyl and 5-6 membered heteroaryl are respectively containing 1, 2, or 3 heteroatoms or heteroatomic groups independently selected from—NH—, —O—, —S-and N.

2 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, R 1 is selected from H, CI, CHF 2 , CF 3 and CH 3 ;
or, R 2 and R 3 are independently selected from H, F, CI, OH and CH 3 .

3 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, R 4 is selected from CH 3 , NH 2 and —NH(CH 3 ).

4 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, X is selected from CH, CF, CCl, CBr and CCH 3 .

5 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, ring A is selected from 5-6 membered heterocycloalkyl, and the 5-6 membered heterocycloalkyl is optionally substituted by 1, 2, or 3 R a .

6 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 5 , wherein, ring A is piperidinyl, and the piperidinyl is optionally substituted by 1, 2, or 3 R a .

7 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 6 , wherein, ring A is selected from

8 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, ring B is selected from C 5-6 cycloalkyl, 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl, and the C 5-6 cycloalkyl, 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl are independently and optionally substituted by 1, 2, or 3 R b .

9 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 8 , wherein, ring B is selected from cyclopentyl, pyrrolidinyl and pyrazolyl, and the cyclopentyl, pyrrolidinyl and pyrazolyl are independently and optionally substituted by 1, 2, or 3 R b .

10 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 9 , wherein, structural unit

is selected from

11 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, structural unit —Y—W is selected from

12 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 11 , wherein, structural unit —Y—W is selected from

13 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, structural unit

is selected from

14 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, R 5 is

15 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 , wherein, the compound is selected from

16 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 15 , wherein, the compound is selected from

17 . A compound or a pharmaceutically acceptable salt thereof, wherein, the compound is selected from

18 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 17 , wherein, the compound is selected from

19 . The compound or the pharmaceutically acceptable salt thereof as defined in claim 17 , wherein, the compound is selected from)

20 . A method for treating breast cancer in a subject in need thereof, comprising: administering a therapeutically effective amount of the compound as defined in claim 1 to the subject.

Assignees

• Medshine Discovery Inc
• Zhejiang Yangli Pharmaceutical Tech Co Ltd

Inventors

• Xu Zhaobing
• Jiang Wen
• Hu Lihong
• Ding Charles Z
• Hu Guoping
• Li Jian
• Chen Shuhui
• Chen Ping
• Yan Xiaobing
• Liu Yingchun

Classifications

• C07D487/04

  Ortho-condensed systems · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title